Latest news

Daily Snap - 17. September 2025

Daily Snap - 17. September 2025

Joachim Eeckhout
Genmab axes ADC from $1.8B ProfoundBio buyout over safety concerns

Genmab axes ADC from $1.8B ProfoundBio buyout over safety concerns

Eduardo Longoria
Apollo's $15M eczema gamble pays off with promising phase 2 win

Apollo's $15M eczema gamble pays off with promising phase 2 win

Eduardo Longoria
Daily Snap - 16. September 2025

Daily Snap - 16. September 2025

Joachim Eeckhout
Novartis expands $5.7B bet on Monte Rosa’s protein-degrading drugs

Novartis expands $5.7B bet on Monte Rosa’s protein-degrading drugs

Eduardo Longoria
Lila Sciences raises $235M to scale AI-driven “scientific superintelligence” labs

Lila Sciences raises $235M to scale AI-driven “scientific superintelligence” labs

Eduardo Longoria
Daily Snap - 15. September 2025

Daily Snap - 15. September 2025

Joachim Eeckhout
Trump-era FDA moves to sideline expert drug reviews, raising alarm

Trump-era FDA moves to sideline expert drug reviews, raising alarm

Eduardo Longoria
Galimedix eyes phase 2 Alzheimer's trial after oral drug clears safety hurdle

Galimedix eyes phase 2 Alzheimer's trial after oral drug clears safety hurdle

Eduardo Longoria
Daily Snap - 12. September 2025

Daily Snap - 12. September 2025

Joachim Eeckhout
Revolution’s daraxonrasib heads to Phase III after strong PDAC trial results

Revolution’s daraxonrasib heads to Phase III after strong PDAC trial results

Eduardo Longoria
FibroGen pays $1.25M to settle SEC allegations over manipulated roxadustat data

FibroGen pays $1.25M to settle SEC allegations over manipulated roxadustat data

Eduardo Longoria
FirstBack
1718192021222324
Next Last